详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China [2]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510275, Guangdong, Peoples R China [3]Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China [4]Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China [5]Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiat Ctr, Guangzhou 510275, Guangdong, Peoples R China

出处：

DOI：

ISSN：

关键词： NON-HODGKINS-LYMPHOMA NASAL-TYPE CLINICAL-SIGNIFICANCE L-ASPARAGINASE RADIOTHERAPY EXPRESSION ANEMIA CYCLOPHOSPHAMIDE GEMCITABINE OXALIPLATIN

摘要：

In this study, we investigated the prognostic role of pretreatment hemoglobin level in 321 patients with stage I/II extranodal natural killer (NK/T cell lymphoma (ENKTL). Patients with pretreatment hemoglobin level < 120 g/L had significantly inferior progression-free survival (PFS) and overall survival (OS) than those with hemoglobin level >= 120 g/L (p < 0.05). In a multivariate Cox regression model, age, Eastern Cooperative Oncology Group (performance status), lactate dehydrogenase level, Ann Arbor stage and pretreatment hemoglobin level were all independent prognostic factors for PFS and OS (p < 0.05). Using these five parameters, a modified international prognostic index (mIPI) model was constructed. This mIPI could categorize three groups with significantly different PFS and OS (both p < 0.0001) in both the training set and the validation set. In conclusion, this study confirmed the prognostic role of pretreatment hemoglobin level in ENKTL, and a newly modified IPI including pretreatment hemoglobin level could be used to further optimize treatments for patients with stage I/II ENKTL, especially in the era of asparaginase.

基金：

基金编号： 04190101 12ykpy54 B2014158 81400159

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 3 区医学

小类 | 4 区血液学 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区血液学 4 区肿瘤学

JCR分区：

出版当年[2013]版：

Q2 HEMATOLOGY Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY Q3 HEMATOLOGY

影响因子： 2.2 最新[2023版] 2.5 最新五年平均 2.605 出版当年[2013版] 2.459 出版当年五年平均 2.301 出版前一年[2012版] 2.891 出版后一年[2014版]

第一作者：

第一作者机构： [1]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China [2]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510275, Guangdong, Peoples R China

通讯作者：

通讯机构： [*1]Sun Yat Sen Univ, Dept Radiat Oncol, Ctr Canc, State Key Lab Oncol South China,Collaborat Innova, Guangzhou 510060, Guangdong, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma [2]First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma [3]CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis [4]Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up [5]Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients [6]Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma [7]Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase [8]CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type [9]High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients [10]Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor